Balyasny Asset Management
REGN icon

Balyasny Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Balyasny Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.31M Sell
1,700
-10,300
-86% -$7.89M ﹤0.01% 1963
2025
Q4 		$9.26M Buy
12,000
+4,600
+62% +$3.12M 0.01% 1063
2025
Q3 		$4.16M Sell
7,400
-7,400
-50% -$4.18M 0.01% 1447
2025
Q2 		$7.77M Buy
+14,800
New +$8.26M 0.01% 1083
2025
Q1 		– Sell
-1,400
Closed -$997K – 3205
2024
Q4 		$997K Sell
1,400
-2,800
-67% -$2.35M ﹤0.01% 1951
2024
Q3 		$4.42M Buy
4,200
+1,900
+83% +$2.11M 0.01% 1312
2024
Q2 		$2.42M Buy
2,300
+1,700
+283% +$1.65M ﹤0.01% 1462
2024
Q1 		$577K Buy
+600
New +$571K ﹤0.01% 1998
2023
Q4 		– Sell
-5,600
Closed -$4.61M – 2829
2023
Q3 		$4.61M Hold
5,600
– – 0.01% 1130
2023
Q2 		$4.02M Hold
5,600
– – 0.01% 1139
2023
Q1 		$4.6M Hold
5,600
– – 0.01% 1117
2022
Q4 		$4.04M Sell
5,600
-100
-2% -$73.8K 0.01% 1121
2022
Q3 		$3.93M Buy
5,700
+4,300
+307% +$2.71M 0.01% 1138
2022
Q2 		$828K Buy
+1,400
New +$910K ﹤0.01% 1825
2021
Q3 		– Sell
-27,400
Closed -$15.3M – 2342
2021
Q2 		$15.3M Buy
+27,400
New +$13.9M 0.07% 370
2020
Q4 		– Sell
-100,000
Closed -$56M – 1631
2020
Q3 		$56M Buy
+100,000
New +$60.6M 0.41% 39
2019
Q4 		– Sell
-135,000
Closed -$37.4M – 1441
2019
Q3 		$37.4M Buy
135,000
+35,000
+35% +$10.4M 0.26% 103
2019
Q2 		$32M Buy
100,000
+63,000
+170% +$21M 0.2% 136
2019
Q1 		$15.2M Buy
+37,000
New +$15.2M 0.1% 287
2018
Q4 		– Sell
-105,500
Closed -$40.5M – 1694
2018
Q3 		$40.5M Buy
105,500
+39,000
+59% +$14.8M 0.18% 146
2018
Q2 		$22.9M Sell
66,500
-42,500
-39% -$13.3M 0.1% 278
2018
Q1 		$37.5M Sell
109,000
-38,500
-26% -$13.4M 0.16% 184
2017
Q4 		$55.5M Buy
+147,500
New +$59.7M 0.17% 149
2017
Q3 		– Sell
-365,000
Closed -$179M – 2061
2017
Q2 		$179M Buy
+365,000
New +$160M 0.74% 12

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Balyasny Asset Management's REGN Position: Q1 2026 in Review

Balyasny Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 98% in Q1 2026, selling an estimated $51.4M and leaving 1,505 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2022.

Balyasny Asset Management first reported a position in REGN in Q2 2013 and has held it in 27 quarters since. The position peaked at $81.1M in Q2 2019. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Balyasny Asset Management held 1,505 shares of Regeneron Pharmaceuticals worth $1.16M as of Q1 2026.
  • Balyasny Asset Management sold 67,080 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $51.4M.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2022 holding.
  • Balyasny Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 27 quarters since.
  • Balyasny Asset Management's Regeneron Pharmaceuticals position peaked at $81.1M in Q2 2019.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.